NOVATO, Calif., Aug. 18, 2023 (GLOBE NEWSWIRE) — Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 42,840 restricted stock units of the company’s common stock to 18 newly hired non-executive officers…Read More
Ultragenyx Pharmaceutical Inc Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635c4
